Techno Polymer Company Limited

Toray Industries, Inc.

Japan Science and Technology Agency

The University of Tokyo

Yamaichi Electronics Co., Ltd.

Tetsuya Kubota

Takashi Kadowaki

Fumio Kurihara

Kazumasa Oota

Masamitsu Takami

Naoto Kubota

Tsuyoshi Matsumoto

Katsumi Suzuki

Takehiro Takahashi

Ryozo Nagai

Toshimasa Yamauchi

Yasushi Imai

Tetsuo Noda

Hiroki Kumagai

Yasuo Terauchi

Akira Genma

Provided is a Kelvin contact for inspection in which contacts and an insulating layer are less likely to be shifted relative to each other even after repeatedly performed Kelvin inspection. The Kelvin contact for inspection includes: a first contact having an upper contact point that comes into contact with one electrode terminal of an IC device and a lower contact point that comes into contact with an electrode pad of a substrate for inspection; and a second contact having an upper contact point that comes into contact with the one electrode terminal and the lower contact point that comes into contact with an electrode pad of the substrate for inspection. The first and second contacts are adjacently arranged to contact with the same one electrode terminal and provided with an insulating layer surrounding the entire main body area except upper and lower contact point areas including the upper and lower contact points, respectively.

Kelvin contact for inspection, kelvin socket for inspection, and method of manufacturing kelvin contact for inspection

A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-&#x3b3; agonist as an effective component which exhibits a reduced side effect of the PPAR-&#x3b3; agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent exhibits a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-&#x3b3; agonists, the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes.

Therapeutic or prophylactic agent for diabetes

A process for producing a thermoplastic resin molded product, comprising: a placement step of placing a thermoplastic resin particle compositionA into a cavityof a rubber diemade of a rubber material; a particle heating step of irradiating the thermoplastic resin particle compositionA in the cavitywith electromagnetic waves having wavelengths ranging from 0.78 to 2 &#x3bc;m through the rubber die, thereby heating to melt the thermoplastic resin particle compositionA; a filling step of filling a thermoplastic resinin a molten state into a spaceleft in the cavity; and a cooling step of cooling a thermoplastic resinin the cavitythereby obtaining a thermoplastic resin molded product.

Process for producing thermoplastic resin molded product and thermoplastic resin particle composition

A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.

Method for treating arteriosclerosis

Growing community of inventors

Tokyo, Japan

Tetsuya Kubota